Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide for the Treatment of CLL Patients With High-Risk Disease

NCT01271283 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01271283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01271283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide for the Treatment of CLL Patients With High-Risk Disease
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2010
Completion date
August 31, 2011
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, stage iii chronic lymphocytic leukemia, stage iv chronic lymphocytic leukemia